Our Solutions
‍

Our Solutions

Advanced Diagnostics.
Closer to the Patient.

Because laboratory-quality diagnostics should be immediately accessible wherever care is delivered.

By combining advanced molecular science with automated workflows, we’re developing diagnostic solutions that bring high-quality testing closer to patients.

As our platform grows, so will our portfolio of solutions—supporting a broad range of clinical applications and helping clinicians make confident decisions with timely diagnostic information.

Our Platform

Lab-Quality Diagnostics.
Closer to Care.

Detect is developing an automated molecular diagnostics platform designed to bring laboratory-quality testing closer to where clinical decisions are made. By combining proprietary chemistry, automated sample preparation, and integrated diagnostic workflows that support a flexible multimodal architecture, we’re building a platform that simplifies complex diagnostics without compromising scientific performance.

Platform Highlights

Proprietary chemistry engineered for rapid, reliable molecular amplification

At the core of Detect’s platform is a proprietary polymerase developed by our scientific team. Rather than building our platform around commercially available enzymes, we engineered our own. Our proprietary Bst polymerase was developed to overcome the performance limitations we encountered while designing next-generation molecular diagnostics, delivering rapid amplification while maintaining robust performance across a wide range of reaction conditions.

‍Key advantages
  • Proprietary enzyme technology optimized for rapid molecular amplification
  • Reliable performance across diverse clinical conditions
  • Proprietary core technology
  • Scalable foundation for future assay development

Automated Sample Preparation within every test cartridge

High-quality molecular diagnostics begin with high-quality sample preparation. Detect automates this traditionally complex laboratory process inside every disposable cartridge, reducing hands-on steps while maintaining laboratory-quality performance.

Designed to deliver‍
  • Automated DNA and RNA purification
  • Integrated sample-to-answer workflow
  • Simplified testing in decentralized care settings

Integrated diagnostic workflows designed to support more complete diagnostic workflows

Many clinical decisions require information from more than one diagnostic method. Detect’s platform is being designed to integrate multiple testing modalities within a single cartridge. Such multimodal technologies create opportunities to simplify complex diagnostic workflows.

Future capabilities include
  • Integration of molecular and serologic testing
  • Multiple laboratory methods within a single workflow
  • Reduced need for multiple instruments or laboratory referrals
  • More comprehensive diagnostic information from a single patient encounter
Explore Vaginitis Testing

Automated sample preparation within every test cartridge [link to more detail]

Integrated diagnostic workflows designed to support more complete diagnostic workflows [link to more detail]

Learn More
For Investigational Use Only
The performance characteristics of this product have not been established.
Explore Vaginitis Testing

A Common Condition.
A Complex Diagnosis.

Vaginitis affects millions of women every year and is one of the most common reasons for visits to an OB/GYN. Yet despite its prevalence, achieving an accurate diagnosis can be surprisingly difficult.  
‍
Vaginitis is the leading reason for OBGYN visits ​
Most women experience Vaginitis at least once in their lifetime​
90% of infectious Vaginitis is caused by 3 conditions​​
The vast majority (90%) of vaginitis is caused by Bacterial Vaginosis, Candida Vaginalis, and Trichomonas Vaginalis infections, either individually or in combination.​
Diagnosis is often challenging and inaccurate​​
Mixed infections and overlapping symptoms can make clinical diagnosis challenging, and manycases are not successfully resolved the first time.​
Advanced diagnostics are still out of reach​
Advances in molecular testing have improved vaginitis diagnosis, but reliance on centralized laboratories can delay results by several days.
‍
Detect is developing a rapid molecular diagnostic solution designed to simplify this process by bringing laboratory-quality testing directly to the point of care. (CTA) Learn More
Learn More

Designed for Fast, Accurate Molecular Results

High Clinical Agreement with an FDA-cleared Comparator
Detect’s investigational vaginitis assay has demonstrated high clinical agreement with an FDA-cleared molecular comparator in preclinical studies, while delivering a fully automated sample-to-answer workflow designed for point-of-care use.
Preclinical studies have demonstrated:
High concordance with an FDA-cleared molecular vaginitis assay
Results within 20 minutes
Automated sample processing with minimal hands-on time
Review our Latest Preclinical Data
Preclinical Performance Highlights*

Detect demonstrated 96.4%–99.4% total agreement across four clinically relevant vaginitis targets when compared with an FDA-cleared molecular assay.

For Investigational Use Only
The performance characteristics of this product have not been established.

*Data on file at Detect, Inc. (treated like a reference)
Discover New Innovations

Future Diagnostic Applications

Innovation doesn’t stop with today’s technology - and neither do we.

At Detect, we’re building more than a diagnostic test. We’re creating a flexible platform designed to grow alongside the changing needs of healthcare. As new diseases emerge, technologies advance, and care continues moving closer to patients, our platform is being designed to adapt and evolve.

By combining proprietary chemistry, automated sample preparation, and a flexible multimodal architecture, we’re laying the foundation for future diagnostic capabilities that can deliver more information with greater simplicity - all from a single, streamlined workflow.

Our Innovation Pipeline